-
Generics Small Molecules: The CDMO Imperative in a Growing Market
As demand for generics small molecules rises, CDMOs must adapt through scalable capacity, rigorous regulatory compliance, and strategic partnerships to stay competitive.
-
CDMOs Poised to Accelerate UF-KureX Solid Tumor Program After $400K NCI Grant
The NCI has awarded $400K to UF and KureX for solid tumor research, highlighting new CDMO collaboration opportunities in oncology biologics, manufacturing, and regulatory support.
-
Single-Use Systems in Biologics Manufacturing: Extractables/Leachables Strategy for CDMO
Transitioning to Single-Use Systems (SUS) offers speed but introduces chemical risks. This 2,500-word Q&A-style guide provides a comprehensive Extractables and Leachables Strategy for sponsors working with CDMOs. Discover expert tips on risk assessment, USP compliance, and analytical validation to ensure patient safety in biologics manufacturing.
-
Drug Substance vs Drug Product Comparability: How CDMO Changes Expand Your Study Scope
Navigating the nuances of Drug Substance vs Drug Product Comparability is vital when switching CDMOs. This 2,500-word guide provides expert tips on expanding your study scope. Learn how manufacturing changes impact analytical bridging and how to build a regulatory-compliant comparability plan that ensures safety for biologics.
-
Plasmid DNA Tech Transfer to a CDMO: Process, Controls, and Release Testing
Plasmid DNA is the backbone of modern gene therapy and mRNA vaccine production. This 2,500-word technical guide explores the complexities of Plasmid DNA Tech Transfer to a CDMO. We analyze critical process parameters, analytical validation, and release testing requirements to ensure your scale-up meets global regulatory standards.
-
Adventitious Agent Testing in Biologics: Building a CDMO Testing Strategy That Regulators Accept
Protecting biologics from viral, bacterial, and fungal contaminants is a regulatory mandate. This 2,500-word guide details Adventitious Agent Testing strategies at CDMOs. Explore in vitro and in vivo assays, Next-Generation Sequencing (NGS) trends, and how to structure your testing program to ensure safety and clinical success.
-
Rapid Mycoplasma Methods in Biologics QC: When CDMOs Can Use Them and How to Validate
Traditional mycoplasma testing takes 28 days, delaying critical patient therapies. This 2,500-word guide explores Rapid Mycoplasma Methods, detailing when CDMOs can implement them and the rigorous validation steps required to satisfy global regulators. Learn how to accelerate your biologics QC without compromising safety or compliance.
-
Cell Bank Characterization (MCB/WCB) at CDMOs: Tests, Timelines, and Red Flags
Establishing a robust Master Cell Bank (MCB) and Working Cell Bank (WCB) is the foundation of biologics manufacturing. This 2,500-word guide explores the technical landscape of cell bank characterization CDMO workflows. We detail essential safety tests, realistic timelines, and the red flags sponsors must watch for to ensure long-term genetic stability.
-
Biologics Tech Transfer Timelines: A Realistic Gantt and What Actually Causes Delays
How long does biologics tech transfer really take? This in-depth guide breaks down realistic timelines, phase-by-phase Gantt planning, and the most common causes of delay when transferring biologics manufacturing to a CDMO.
-
Biologics CDMO Outsourcing Strategy
Developing a robust biologics outsourcing strategy is essential for biotech sponsors navigating the high-stakes large-molecule market. This technical guide explores strategic triggers, partnership models, and risk mitigation frameworks, providing a roadmap for successful long-term CDMO collaborations from clinical phases to commercial launch in 2026.
Categories
Latest Articles